Pancreatic Neuroendocrine Tumors (pNETs): Symptoms, Types, Diagnosis and Treatment (2026 Guide)

Medically reviewed content · Published 2026 · Last reviewed August 2026

Pancreatic neuroendocrine tumors (pNETs) are tumors that arise from neuroendocrine cells in the pancreas — the hormone-producing islet cells, rather than the exocrine ducts and glands that give rise to the far more common pancreatic ductal adenocarcinoma. pNETs are biologically distinct from that more common pancreatic cancer, generally behave differently, and are managed by a different treatment framework. Some pNETs are functional, producing hormones in amounts large enough to cause a recognizable clinical syndrome — insulinoma, gastrinoma, glucagonoma, VIPoma, and somatostatinoma are the named functional types.

Most, however, are nonfunctional — they may still produce hormones biologically, but not enough to cause a hormone-related illness, and are often found incidentally or once they’ve grown large enough to cause symptoms from their size alone. pNETs are further divided into well-differentiated tumors (graded 1 to 3) and the biologically distinct, more aggressive poorly differentiated pancreatic neuroendocrine carcinoma (NEC).

This guide explains the different types of pNET, how they’re diagnosed and graded, and current treatment options — including pancreatic surgery, somatostatin analogues, PRRT with Lutetium-177 DOTATATE, targeted therapy, and liver-directed treatment for metastatic disease along with what pNET treatment and its cost look like for international patients considering care in India. This is general medical education, not a diagnosis or an individual treatment recommendation.

pNET vs. Pancreatic Ductal Adenocarcinoma

It’s important not to assume pNETs are automatically slower-growing or easier to treat than pancreatic adenocarcinoma — behavior varies enormously by grade and differentiation, discussed below, and the two cancers are simply not comparable using the same yardstick.

Well-differentiated pNET vs. poorly differentiated pancreatic NEC

This is a second, equally important distinction, separate from the comparison above. Well-differentiated pancreatic neuroendocrine tumors retain organized, recognizable neuroendocrine architecture under the microscope and are graded 1 through 3 based on proliferation rate.

Poorly differentiated pancreatic neuroendocrine carcinoma (NEC) is a biologically distinct, disorganized, automatically high-grade cancer that behaves much more aggressively and is generally treated with a different systemic therapy strategy centered on platinum-based chemotherapy rather than the somatostatin-analogue- and PRRT-based approaches used for well-differentiated disease. “NET” and “NEC” are not interchangeable terms, even though both fall under the broader neuroendocrine neoplasm umbrella — treatment planning depends on knowing which one you actually have.

Functional vs. Nonfunctional pNET

“Nonfunctional” is a clinical description, not proof of zero hormone production — it specifically means the tumor isn’t causing a recognizable hormone-driven illness, which is a distinction worth understanding since the term can otherwise sound more absolute than it is.

Types of Functional pNET

Insulinoma

Usually produces excess insulin, which can cause hypoglycemia (low blood sugar) — symptoms may include sweating, tremor, intense hunger, confusion, weakness, or, in severe cases, loss of consciousness. Clinically, insulinoma is classically associated with Whipple’s triad: symptoms of hypoglycemia, a documented low blood glucose at the time of symptoms, and relief of symptoms once glucose is given — though this is something your medical team assesses and documents, not something to test at home. Insulinoma cannot be diagnosed from symptoms alone; it requires supervised biochemical evaluation.

Gastrinoma

Produces excess gastrin, driving excessive stomach acid production. This can cause recurrent peptic ulcers, abdominal pain, and diarrhea — a pattern historically called Zollinger-Ellison syndrome. Gastrinomas have a meaningful association with the hereditary MEN1 syndrome (discussed below) and can arise in either the pancreas or the nearby duodenum.

Glucagonoma

Produces excess glucagon, which can cause hyperglycemia (high blood sugar, sometimes diagnosed as diabetes), a characteristic skin rash called necrolytic migratory erythema in some patients, and weight loss. Not every patient develops every feature of this syndrome — presentations vary.

VIPoma

Produces vasoactive intestinal peptide (VIP), which can cause severe, high-volume watery diarrhea, significant electrolyte disturbances (particularly low potassium), and dehydration — a pattern sometimes called WDHA syndrome (watery diarrhea, hypokalemia, achlorhydria). This can become medically urgent quickly given how much fluid and electrolyte loss can occur.

Somatostatinoma

Produces excess somatostatin, which can cause diabetes or hyperglycemia, gallstones, and digestive symptoms including fatty, poorly absorbed stools. Somatostatinomas can arise in either the pancreas or the duodenum, and the full syndrome isn’t always completely present in every patient.

Other hormone-producing pNETs

Rarer functional pNETs exist — including tumors producing pancreatic polypeptide, which is generally not a reliable stand-alone diagnostic marker, or, uncommonly, ACTH or other hormones — but these are uncommon enough that they’re best discussed individually with your treating endocrinologist or NET specialist rather than covered in exhaustive detail here.

Symptoms by hormone

Functional pNET emergencies

Severe hormone excess can occasionally cause medically urgent situations — severe hypoglycemia from an insulinoma causing confusion or loss of consciousness, severe dehydration and electrolyte disturbance from a VIPoma, or acid-related complications (such as bleeding or perforated ulcers) from a gastrinoma.

These situations require urgent medical assessment, not self-management — if you or someone you’re caring for has a known functional pNET and develops severe or rapidly worsening symptoms consistent with these patterns, seek emergency care rather than waiting for a routine appointment.

Symptoms of Nonfunctional pNET and General Symptoms

Beyond the hormone-specific syndromes above, symptoms vary by tumor size, location, local invasion, and whether metastatic disease is present. General symptoms can include abdominal or back pain, nausea, unexplained weight loss, jaundice (if the tumor affects bile flow), and loss of appetite. Many nonfunctional pNETs cause no symptoms at all and are discovered incidentally during imaging done for an unrelated reason.

Causes and Risk Factors

The exact cause of most sporadic (non-inherited) pNETs is unknown. A minority of pNETs occur as part of hereditary syndromes, most notably:

• Multiple endocrine neoplasia type 1 (MEN1)
• Von Hippel-Lindau (VHL) syndrome
• Neurofibromatosis type 1 (NF1)
• Tuberous sclerosis complex

Hereditary pNETs represent a minority of overall cases — most patients diagnosed with a pNET do not have one of these syndromes, and a pNET diagnosis alone doesn’t mean a hereditary cause is likely.

MEN1 and pNETs

MEN1 (multiple endocrine neoplasia type 1) is a hereditary endocrine tumor syndrome that can involve the parathyroid glands, the pituitary gland, and pancreatic or duodenal neuroendocrine tumors — often multiple pNETs rather than a single tumor. Genetic counseling and testing may be appropriate for selected patients, discussed further below, but this is an individualized decision made with a genetics specialist, not something this guide can determine for any specific reader.

Should patients with pNETs have genetic testing?

Genetic evaluation may be appropriate for patients with young age at diagnosis, multiple pancreatic tumors (multifocal disease), a personal or family history suggestive of MEN1 or another hereditary syndrome, or other endocrine tumors alongside the pNET. Not every patient with a pNET needs genetic testing — it’s a decision made with a genetic counselor or NET specialist based on individual clinical features, not a routine step for every diagnosis.

How pNETs Are Diagnosed

1. Clinical history and, where relevant, hormonal evaluation
2. Blood and biochemical testing
3. CT, MRI, and/or endoscopic ultrasound
4. Somatostatin-receptor imaging where relevant
5. Biopsy when needed
6. Pathology, including Ki-67 and mitotic assessment
7. Staging
8. Multidisciplinary treatment planning

Blood and hormone testing

Testing depends on whether a functional syndrome is suspected. Depending on the clinical picture, tests may include fasting glucose, insulin, C-peptide, and proinsulin (for suspected insulinoma, generally during a supervised fasting evaluation), gastrin, glucagon, VIP, or somatostatin. Chromogranin A may be elevated in some neuroendocrine tumors and is sometimes used as a general marker, but it is not specific enough to diagnose a pNET on its own — levels can be affected by certain medications (notably proton pump inhibitors) and other medical conditions, so it’s interpreted in clinical context rather than as a stand-alone test. Not every patient needs every hormone test — testing is guided by symptoms and clinical suspicion.

Imaging

Contrast-enhanced CT and MRI provide detailed information about tumor size, location, and relationship to nearby structures, including the pancreatic duct and major blood vessels. Endoscopic ultrasound (EUS) can detect small pancreatic lesions that may be missed on cross-sectional imaging, characterize the mass in more detail, evaluate nearby structures, and allow tissue sampling in the same procedure when appropriate.

Somatostatin-receptor imaging — most often Ga-68 DOTATATE PET/CT — takes advantage of the fact that many well-differentiated pNETs express somatostatin receptors (particularly the SSTR2 subtype) on their cell surface. This imaging helps stage disease, detect metastases that might not be visible on standard CT or MRI, confirm receptor expression, and identify patients who may be candidates for PRRT. Not every pNET is strongly receptor-positive, so this scan doesn’t apply identically to every patient. FDG PET/CT is used differently — it’s particularly useful in higher-grade, more aggressive tumors, or poorly differentiated NEC, and provides different biological information than somatostatin-receptor imaging rather than serving as an interchangeable alternative.

Biopsy and pathology

Biopsy may be used when the diagnosis is uncertain, histologic confirmation is needed before starting treatment, or metastatic disease needs to be characterized — but not every resectable pancreatic lesion necessarily requires a biopsy before surgery, depending on the clinical picture and imaging findings. Pathology evaluates neuroendocrine differentiation, tumor morphology, mitotic activity, necrosis, and relevant immunohistochemistry, including markers like synaptophysin and chromogranin — no single marker establishes the diagnosis alone.

Ki-67 and WHO grade

Ki-67 measures the proportion of tumor cells actively dividing at the time of sampling — a proliferation index that is central to grading well-differentiated pNETs. Higher Ki-67 generally indicates a more proliferative, potentially more aggressive tumor. Current WHO grading for well-differentiated pancreatic NETs uses these general categories:

Grade and stage are different concepts and are not interchangeable: grade describes how quickly the tumor is proliferating; stage describes how far it has spread. A low-grade tumor can still be metastatic — for example, a Grade 1 pNET that has spread to the liver is still Grade 1, just at a more advanced stage — and both pieces of information matter together for treatment planning and prognosis.

Staging

pNET staging considers the size and local extent of the primary pancreatic tumor, regional lymph node involvement, and the presence of distant metastases — most commonly to the liver. Current AJCC staging criteria specific to pancreatic neuroendocrine tumors differ somewhat from the staging system used for pancreatic ductal adenocarcinoma, reflecting their different biology; your pathology and imaging reports, interpreted by your treating team using pNET-specific staging criteria, are what determine your specific stage. In general terms, Stage I–III describe increasing local and regional extent, while Stage IV indicates distant metastatic disease — but Stage IV does not automatically mean terminal or untreatable disease for pNETs, since well-differentiated metastatic disease, particularly lower-grade disease, can often be managed for years.

pNET Treatment Overview

Treatment depends on functional status, grade, differentiation, stage, tumor size and location, resectability, somatostatin-receptor expression, growth rate, liver involvement, symptoms, prior treatment, and overall health. Available approaches include active surveillance, surgery, somatostatin analogues, PRRT, targeted therapy, chemotherapy, liver-directed therapy, and, in selected cases, radiation or clinical trials. Most patients are managed by a multidisciplinary team including a NET-specialist oncologist, pancreatic surgeon, gastroenterologist, endocrinologist, and nuclear medicine physician.

Active surveillance

Selected small, low-grade, asymptomatic pNETs — particularly small nonfunctional tumors under a certain size — may be monitored with periodic imaging rather than treated immediately. Factors influencing this decision include tumor size, grade, growth rate on serial imaging, functional status, location, symptoms, and patient preference. This is an individualized decision made with a specialist; it is not appropriate to decide on observation without a full specialist assessment of the specific tumor’s features.

Surgery

Surgery is the main potentially curative treatment for localized, resectable pNETs in appropriate patients. The specific procedure depends heavily on tumor location, size, relationship to the pancreatic duct, grade, functional status, and whether there’s local invasion:

• Enucleation — removal of just the tumor itself, leaving the surrounding pancreas intact. May be considered for small tumors that are favorably located and sufficiently distant from the main pancreatic duct, preserving the most pancreatic function.
• Central pancreatectomy — removes only the neck and upper body of the pancreas, keeping the head and tail intact, an option for small, low-grade tumors in that specific location when enucleation isn’t safely possible.
• Distal pancreatectomy — used for tumors in the body or tail of the pancreas; the spleen is often removed alongside the tail, though splenic preservation can be considered in select situations. Because splenectomy increases susceptibility to certain infections, specific vaccinations are generally recommended beforehand when the spleen will be removed.
• Pancreaticoduodenectomy (Whipple procedure) — used for tumors in the head of the pancreas that can’t be removed by enucleation, removing the pancreatic head, the duodenum, the gallbladder, and the bile duct together, followed by reconstruction. This is a major operation with meaningfully more complexity and recovery time than the other options.

Regional lymph node assessment is generally performed alongside tumor removal to help with accurate staging. Not every pancreatic-head pNET requires a Whipple procedure — smaller, favorably located tumors may sometimes be managed with a less extensive approach — and the right procedure for a specific tumor is a decision made by an experienced pancreatic surgeon based on detailed imaging.

Somatostatin Analogues: Octreotide and Lanreotide

Octreotide and lanreotide are somatostatin analogues — medications that bind to somatostatin receptors on eligible tumor cells. They serve two roles: controlling hormone-related symptoms in functional pNETs (particularly effective for VIPoma and somatostatinoma symptoms, and used as part of managing carcinoid-type symptoms when relevant), and, in selected well-differentiated, receptor-positive pNETs, helping control tumor growth itself, not just symptoms.

They are not chemotherapy, and they work through a different mechanism than PRRT, discussed next — though both PRRT and somatostatin analogues rely on the same underlying somatostatin-receptor biology. Octreotide and lanreotide are similar in mechanism and clinical use; they differ mainly in their specific formulation and dosing schedule, a distinction your treating oncologist will discuss based on practical considerations for your situation, not a difference this guide can meaningfully rank.

PRRT for Pancreatic NETs

Peptide receptor radionuclide therapy (PRRT) uses a radiolabeled somatostatin analogue to deliver targeted radiation directly to somatostatin-receptor-positive tumor cells throughout the body. Lutetium-177 DOTATATE is the PRRT agent most widely used for pancreatic and other gastroenteropancreatic NETs, generally given as a course of several infusion cycles.

PRRT eligibility for pNETs specifically depends on confirmed somatostatin-receptor expression on prior imaging, the tumor’s grade and differentiation (PRRT is generally used in well-differentiated disease, not poorly differentiated NEC), evidence of disease progression or an otherwise appropriate clinical situation, adequate kidney and bone marrow function, and prior treatment history. A positive DOTATATE scan alone does not guarantee PRRT eligibility — the full clinical picture is assessed by a nuclear medicine specialist.

Potential risks of Lutetium-177 DOTATATE include nausea and fatigue around the time of infusion, bone marrow suppression, potential kidney effects (monitored closely, with protective measures given during treatment), liver considerations, hormonal effects in some patients, and — a recognized but uncommon long-term risk — the development of a blood disorder such as myelodysplastic syndrome years after treatment, which is why bone marrow function continues to be monitored after the treatment course ends.

Targeted Therapy: Everolimus and Sunitinib

Everolimus, an mTOR inhibitor, has an established role in selected advanced pancreatic NETs, where it can help slow tumor progression in appropriate patients; common considerations include its effects on the immune system and metabolism, discussed with your treating oncologist. Sunitinib, a tyrosine kinase inhibitor targeting pathways including VEGF signaling, also has an established role in selected advanced pancreatic NETs. Neither drug is appropriate for every patient — selection depends on prior treatment, tumor characteristics, and individual tolerance — and specific dosing and monitoring are managed by the treating oncology team.

Chemotherapy: CAPTEM and NEC-Specific Treatment

Chemotherapy is considered particularly for higher-grade disease, rapidly progressive tumors, larger tumor burden, and selected advanced pNETs where other systemic options haven’t controlled the disease. CAPTEM — a combination of capecitabine (CAP) and temozolomide (TEM) — is a commonly used regimen in selected advanced, well-differentiated pancreatic NETs, though it is not universally superior to other systemic therapy options; the right sequence of treatments is an individualized decision.

Poorly differentiated pancreatic NEC is treated differently — this is a genuinely distinct disease from well-differentiated pNET, and systemic treatment generally centers on platinum-based chemotherapy (often combined with etoposide), reflecting how much more aggressively these tumors typically behave. Well-differentiated pNET and poorly differentiated NEC should not be treated using the same systemic therapy algorithm, even though both fall under the broader neuroendocrine neoplasm category.

Liver Metastases and Metastatic pNET

The liver is a common site of metastatic spread for pancreatic NETs. Treatment options depend on how disease is distributed:

Multidisciplinary evaluation — typically involving a hepatobiliary or interventional radiology specialist alongside the NET oncology team — is important for determining which combination applies to a specific patient, since not every patient with liver metastases is a candidate for liver-directed surgery or ablation.

Treatment goals and approach for metastatic pNET more broadly depend heavily on grade, differentiation, somatostatin-receptor expression, tumor burden, growth rate, and symptoms — metastatic disease, especially well-differentiated, lower-grade disease, is not equivalent to immediate end-stage illness, and many patients are managed for years with a combination of the approaches above.

Metastases to bone can also occur, causing bone pain, increased fracture risk, and, in the spine, a risk of spinal cord compression requiring urgent evaluation if new weakness or numbness develops. Management may include systemic therapy, radiation for symptom control, and orthopedic intervention where needed.

Recurrent pNET

Recurrence can occur after surgery or systemic therapy. Treatment depends on the site of recurrence, grade, growth rate, previous treatment received, current receptor expression, and whether the recurrence is resectable. Options include repeat surgery, somatostatin analogues, PRRT, targeted therapy, chemotherapy, liver-directed therapy, or clinical trial participation — there is no single universal approach to recurrence, and the right combination depends on the specific pattern of recurrent disease.

Prognosis and Survival

pNET prognosis depends on grade, differentiation, stage, tumor burden, liver involvement, functional status, somatostatin-receptor expression, growth rate, and response to treatment — pNETs vary enormously in behavior, from indolent Grade 1 tumors managed for many years to aggressive, poorly differentiated NEC requiring urgent intensive treatment. This guide will not give a single “pNET survival rate,” since no single number reflects this range.

If you encounter a specific survival statistic, check whether it specifies grade, stage, the study population, the treatment era, and follow-up period — and note that pNET survival statistics should never be combined with pancreatic ductal adenocarcinoma statistics, since the two cancers behave very differently and combining them would meaningfully distort what either number actually means.

Long-term follow-up

Because pNETs — particularly well-differentiated ones — can recur or progress slowly over many years, long-term surveillance is standard, generally including clinical assessment, hormonal evaluation where relevant, CT or MRI imaging, somatostatin-receptor imaging when clinically indicated, and monitoring for treatment-related toxicity. Your specialist team will set a surveillance schedule tailored to your specific tumor’s grade and behavior — there’s no single universal interval that applies to every patient.

Pancreatic Neuroendocrine Tumor Treatment Cost in India

There is no single “pNET treatment cost” — total cost depends on which combination of surgery, systemic therapy, and follow-up a specific patient needs. Below is a component breakdown; costs for diagnostics, somatostatin analogues, and PRRT are consistent with current NET-treatment pricing patterns generally, while surgical figures are pNET/pancreatic-surgery-specific.

Why International Patients Consider India for pNET Care, and How to Choose a Center

India has developed substantial capability in neuroendocrine oncology, pancreatic surgery, and nuclear medicine/theranostics, including access to DOTATATE PET/CT and PRRT — for international patients, the appeal is typically this combination of capability with costs generally lower than the US, UK, or much of Europe. India isn’t automatically “the best” choice for every patient, however; several countries offer strong NET and pancreatic surgery programs, and the right choice depends on an individual patient’s specific disease, budget, and travel considerations.

When evaluating a center for pNET care — in India or anywhere — look for:

• A NET-specialist oncologist and experienced pancreatic surgeon, not general oncology or general surgery coverage alone
• A gastroenterologist and endocrinologist for functional syndrome management
• A nuclear medicine physician with DOTATATE PET/CT and PRRT capability
• An interventional radiologist for liver-directed therapy
• Advanced pathology with reliable Ki-67 turnaround
• A genuine multidisciplinary NET tumor board
• Clinical trial access, where relevant
• Established international patient services (visa letters, coordination, interpreter support)

Verify accreditation, named specialist credentials, and specific PRRT and pancreatic surgery case volume directly with the hospital, rather than relying solely on third-party “top hospital” listicles.

The International Patient Treatment Journey

1. Share existing medical records and imaging for review
2. Confirm pathology and functional status
3. Determine differentiation and grade, including Ki-67
4. Stage the disease
5. Assess somatostatin-receptor expression where relevant
6. Multidisciplinary specialist review
7. Treatment plan developed, with alternatives explained
8. Hospital and specialist confirmation
9. Written, itemized cost estimate
10. Medical visa guidance
11. Travel and accommodation arrangements
12. Treatment delivery
13. Response monitoring
14. Long-term follow-up planning
15. Remote follow-up and report-sharing with the home-country physician

No credible provider can guarantee a diagnosis, surgical eligibility, PRRT eligibility, treatment response, cure, an exact final cost, visa approval, or survival outcome before reviewing a patient’s actual pathology and imaging — be cautious of any provider offering these guarantees upfront.

Questions to Ask Your pNET Team

• Is my tumor a well-differentiated pNET or a poorly differentiated NEC?
• Is it functional or nonfunctional, and which hormone, if any, is involved?
• What is my Ki-67 index and WHO grade?
• What is my stage?
• Is the tumor resectable, and which surgical approach (enucleation, distal pancreatectomy, or Whipple) would be used?
• Are lymph nodes involved? Are there liver metastases?
• Does my tumor express somatostatin receptors, and should I have a DOTATATE PET/CT?
• Am I a candidate for PRRT?
• Would octreotide or lanreotide help my symptoms or tumor control?
• Is everolimus or sunitinib appropriate for my situation?
• Would CAPTEM or another chemotherapy regimen be appropriate?
• Should I consider liver-directed treatment?
• Do I need genetic testing for MEN1 or another hereditary syndrome?
• What is the overall goal of my treatment plan?
• How will my tumor be monitored going forward?

How Shifam Health Helps International pNET Patients

Shifam Health is a medical tourism facilitator, not a cancer hospital, NET treatment center, nuclear medicine department, or pancreatic surgery center — we don’t diagnose pNETs or determine treatment plans. What we do is help international patients navigate the practical side of accessing pNET care in India: coordinating the review of pathology and imaging by relevant specialists, helping shortlist hospitals with genuine pancreatic NET and PRRT experience, obtaining written treatment and cost estimates, assisting with medical visa documentation, arranging airport pickup and accommodation, providing interpreter support where needed, and staying in touch for follow-up communication once you return home.

If you or someone you’re caring for has received a pNET diagnosis, share your available reports with our team on WhatsApp or through a quick inquiry form — there’s no obligation, and we typically respond within 24 hours.

Conclusion

Pancreatic neuroendocrine tumors are a genuinely diverse group of diseases — functional status, differentiation, Ki-67 grade, stage, and somatostatin-receptor expression together determine what a specific pNET diagnosis means and which combination of surgery, somatostatin analogues, PRRT, targeted therapy, or liver-directed treatment is appropriate. If you or someone you’re caring for has been diagnosed with a pNET, understanding these distinctions — and asking direct questions about your own pathology and grade — is the most useful step before deciding on a treatment path, in India or anywhere else.

Frequently Asked Questions

This article is for general medical education and does not replace individualized advice from a qualified endocrinologist, gastroenterologist, pancreatic surgeon, or nuclear medicine specialist. It is not a diagnosis, treatment recommendation, or guarantee of any outcome.